Gefitinib

SKU: orb1309499

Description

Gefitinib

Research Area

Cardiovascular Research, Cell Biology, Signal Transduction

Key Properties

• CAS Number: 184475-35-2
• MW: 446.9
• Purity: 100.00%
• Formula: C₂₂H₂₄ClFN₄O₃
• SMILES: N(C=1C2=C(C=C(OC)C(OCCCN3CCOCC3)=C2)N=CN1)C4=CC(Cl)=C(F)C=C4
• Target: Apoptosis,Autophagy,EGFR,Tyrosine Kinases
• Solubility: DMSO:18.33 mg/mL (41.02 mM);Ethanol:4.5 mg/mL (10.07 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4.47 mg/mL (10 mM)

Bioactivity

• Target IC50:
  Tyr992:57 nM (NR6W cells)|Tyr992:37 nM (NR6wtEGFR cells)|Tyr1173:26 nM (NR6W cells)|Tyr1173:37 nM (NR6wtEGFR cells)
• In Vivo:
  METHODS: To detect anti-tumor activity in vivo, Gefitinib (3.125-200 mg/kg in 0.5% polysorbate 80) was administered orally to nude mice harboring tumors A431, Du145, or A549 once a day for seven to fifteen days. RESULTS: Gefitinib inhibited the growth of A431, Du145 or A549 tumors in a dose-dependent manner. METHODS: To assay antitumor activity in vivo, Gefitinib (40 mg/kg once daily) or Gefitinib (200 mg/kg every five days) was administered by gavage for two weeks to athymic nude mice harboring the human lung cancer tumor H3255. RESULTS: Weekly treatment showed better inhibition than daily treatment. Compared with the daily dosing regimen, the weekly dosing regimen showed stronger inhibition of p-EGFR, p-ERK, and p-AKT.
• In Vitro:
  METHODS: Twenty-three tumor cells were treated with Gefitinib for 72 h, and cell viability was measured by MTT. RESULTS: Only the PC9 cell line had an IC50 <1 μmol/L (highly sensitive), 14 cell lines had an IC50 >10 μmol/L (resistant), and the remaining 8 cell lines had an IC50 of 1-10 μmol/L (moderately sensitive). METHODS: Tumor cells HT29, KB, Du145 and A549 were treated with Gefitinib (0.032-50 μM) for 2 h. EGF (0.1 μg/mL) was added five minutes prior to cell lysis, and the expression levels of target proteins were detected using Western Blot. RESULTS: Gefitinib produced a dose-dependent inhibition of EGFR autophosphorylation in all tumor cell lines.
• Cell Research:
  The human NSCLC H1299, H1975, A549, H460, GLC82, H460, and CALU-3 cell lines were provided by the American Type Culture Collection and maintained in RPMI-1640 supplemented with 10% FBS in a humidified atmosphere with 5% CO2. CALU-3 GEF-R is a cell line obtained in vitro as previously described. Briefly, over a period of 12 months, human CALU-3 lung adenocarcinoma cells were continuously exposed to increasing concentrations of gefitinib. The starting dose was the dose causing the inhibition of 50% of cancer cell growth (IC50; gefitinib, 1 μmol/L). The drug dose was progressively increased to 15 μmol/L in approximately 2 months, to 20 μmol/L after other 2 months, to 25 μmol/L after additional 2 months, and, finally, to 30 μmol/L for a total of 12 months. The established resistant cancer cell lines were then maintained in continuous culture with the maximally achieved dose of each TKI that allowed cellular proliferation (30 μmol/L for each drug) .
• Animal Research:
  Four- to 6-week old female balb/c athymic (nu+/nu+) mice were purchased from Charles River Laboratories. Mice were acclimatized for 1 week before being injected with cancer cells and injected subcutaneously with 107 H1299 and CALU-3 GEF-R cells that had been resuspended in 200 μL of Matrigel. When established tumors of approximately 75 mm3 in diameter were detected, mice were left untreated or treated with oral administrations of metformin (200 mg/mL metformin diluted in drinking water and present throughout the experiment), gefitinib (150 mg/kg daily orally by gavage), or both for the indicated time periods. Each treatment group consisted of 10 mice. Tumor volume was measured using the formula π/6 × larger diameter × (smaller diameter)2. Tumor tissues were collected from the xenografts and analyzed by Western blotting for the expression and activation of EGFR, AMPK, mitogen-activated protein kinase (MAPK), and S6 .

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

phosphorylation, ZD 1839, ZD1839, ZD-1839, TAMs, tumor metastasis, Tyrosine Kinases, TyrosineKinases, Tyr1173 (NR6wtEGFR cells), Tyr992, Tyr992 (NR6W cells), Tyr992 (NR6wtEGFR cells), Tyr1173 (NR6W cells), breast cancer, antitumour, Apoptosis, Autophagy, Inhibitor, Gefitinib, HER1, ErbB-1, Epidermal growth factor receptor, EGFR tyrosine kinase, EGFR, lung cancer, inhibit, NSCLCs

Compound Identifiers

PubChem CID

123631